Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Account Payables
Amounts the company owes suppliers for goods and services received.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 18.9% from a year ago
Account payables stood at $1.01M at the end of Q1 FY2026, down 18.9% from a year earlier and up 236.9% from the prior quarter. Over 3 fiscal years it compounded at -29.1% a year.
Context
- Account payables amounted to 1.6% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -18.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 301K USD
- Year-over-year change
- -68.8%
- 4-year CAGR
- -20.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 301K | -68.8% |
| FY2024 | 2024-12-31 | 966K | +17.7% |
| FY2023 | 2023-12-31 | 821K | -3.0% |
| FY2022 | 2022-12-31 | 846K | +14.0% |
| FY2021 | 2021-12-31 | 742K | — |
Account Payables vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -18.9% is the 4th highest of 10, against a peer median of -23.5%.
- Account payables amounts to 1.6% of total assets for UNCY, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $24.19M USD | +45.5% | +57.4% | 13.4% | |
| Mar 2026 | $10.51M USD | +90.9% | +33.3% | 5.5% | |
| Mar 2026 | $5.73M USD | +353.1% | -33.2% | 2.4% | |
CBUSCibus, Inc. | Mar 2026 | $5.41M USD | -20.2% | +187.4% | 1.7% |
| Mar 2026 | $4.61M USD | -40.1% | -22.1% | 9.9% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3.36M CAD | -23.5% | +10.5% | 14.5% |
| Mar 2026 | $1.63M USD | -54.6% | +1.7% | 1.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.16M USD | -68.5% | +36.1% | 1.1% |
| Mar 2026 | $1.01M USD | -18.9% | -29.1% | 1.6% | |
| Mar 2026 | $863K USD | -38.3% | — | 0.8% | |
| Peer median (excluding UNCY) | — | -23.5% | +21.9% | 2.4% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.